Montreal, July 8, 2021 - Earlier this year, a team of researchers with the Lady Davis Institute (LDI) at the Jewish General Hospital (JGH) and the Biobanque Quebec COVID-19 discovered that people who had elevated levels of the protein OAS1 experienced less severe illness and lower rates of mortality when infected with COVID-19. In a paper published in Nature Medicine, they posited that small molecules capable of boosting OAS1 warranted further study for their effect in triggering the body’s immune response against the virus.
See attachment for more details.